Potential for therapy of drugs and hyperthermia.
Potential for therapy of drugs and hyperthermia.
复制标题
药物和热疗治疗的潜力。
作者：
G. Hahn
热疗（41- 45 ℃）和化学治疗剂的相互作用经常导致细胞毒性增加，超过预测的累加效应，尽管迄今为止只有非常有限数量的药物被检测出这种可能的相互作用。在42摄氏度，对全身热疗有用的温度上限，迄今为止检查的那些最有希望的药剂似乎是亚硝基脲和顺铂。环磷酰胺的数据不足，其较长的血浆半衰期使其成为一种有吸引力的候选药物。局部加热似乎在较高的温度（43- 45摄氏度）最佳。在这些温度下，不仅那些在42摄氏度有效的药物，而且特别是博来霉素和可能的阿替霉素B成为候选药物。文献中没有关于可能的“热致敏剂”的数据，即，在37 ℃下无细胞毒性但在高温下有效的药物。两种特殊情况是阿霉素和放线菌素D。这些药物可能是禁忌的临床使用，因为不仅协同作用，而且还保护热已被证明，这取决于时间序列关系的热和药物治疗。
The interaction of hyperthermia (41--45 degrees C) and chemotherapeutic agents frequently results in increased cytotoxicity over that predicted for an additive effect, although to date only a very limited number of drugs have been examined for such a possible interaction. At 42 degrees C, the upper limit of temperature useful for whole-body hyperthermia, the most promising agents of those examined to date appear to be the nitrosoureas and cis-platinum. Insufficient data exist for cyclophosphamide, whose long plasma half-life makes it an attractive candidate. Localized heating seems optimum at higher temperatures (43--45 degrees C). At these temperatures, not only those drugs effective at 42 degrees C but particularly bleomycin and possibly amphotericin B become candidates. No data exist in the literature on possible "thermic sensitizers," i.e., drugs which are noncytotoxic at 37 degrees C but which become effective at elevated temperatures. Two special cases are Adriamycin and actinomycin D. These drugs may be contraindicated for clinical use, since not only synergism but also protection by hyperthermia have been demonstrated, depending upon the time-sequence relationships of the heat and drug treatments.